> ## Content Index
> Fetch the complete content index at: https://chinapharmadesk.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Windward Bio's $225 million Nasdaq debut tests China's equity-linked respiratory NewCo model
- URL: https://chinapharmadesk.com/windward-bio-ipo-kelun-harbour-qyuns/
- Published: 2026-11-15T14:16:48.000Z
- Updated: 2026-11-15T14:16:51.000Z
- Description: Windward Bio (NASDAQ: WWB) priced a $175 million IPO and $50 million Sanofi placement on Nov 12, 2026, putting Kelun-Biotech (06990.HK), Harbour BioMed (02142.HK), and Qyuns (02509.HK) assets in public hands.
- Author: Lin Yi
- Tags: Desk brief, Deals & BD, Capital, Autoimmune & Immunology

Basel-based [Windward Bio Group AG](https://www.sec.gov/Archives/edgar/data/2145089/000119312526458885/d190875dfwp.htm?ref=chinapharmadesk.com) (NASDAQ: WWB) priced its $175 million U.S. initial public offering and a concurrent $50 million Sanofi private placement on November 12, 2026, beginning Nasdaq trading on November 13 ahead of a scheduled November 16 closing. Rather than internal discovery, Windward’s entire clinical pipeline rests on two ultra-long-acting respiratory antibodies in-licensed from Chinese biotechs—putting equity stakes and up to $1.6 billion in downstream milestones held by [Harbour BioMed](https://www.harbourbiomed.com/news/1432.html?ref=chinapharmadesk.com) (HKEX: 02142), [Sichuan Kelun-Biotech](https://www.harbourbiomed.com/news/1482.html?ref=chinapharmadesk.com) (HKEX: 06990), and [Qyuns Therapeutics](https://stockn.xueqiu.com/02509/20260819993835.pdf?ref=chinapharmadesk.com) (HKEX: 02509) directly onto U.S. public markets.

The listing tests the second act of China’s “NewCo” out-licensing wave: taking small cash-plus-equity upfronts to let an offshore, venture-backed vehicle fund expensive Phase III respiratory trials, while Chinese originators retain Greater China commercial rights and ride any U.S. public-market re-rating.

## $225 million financing and the Chinese asset stack

Under its [November 12 SEC free writing prospectus](https://www.sec.gov/Archives/edgar/data/2145089/000119312526458885/d190875dfwp.htm?ref=chinapharmadesk.com) (relating to Form F-1 File No. `333-299608`), Windward sold 10,294,117 common shares at $17.00—the midpoint of its $16–$18 range—for $175.0 million in gross IPO proceeds (excluding a 30-day underwriters’ option for 1,544,117 shares), alongside Sanofi Foreign Participations B.V.’s concurrent $50.0 million purchase of 1,532,691 shares and 1,408,485 pre-funded warrants at the same price. Estimated net proceeds stand at $203.8 million, lifting Windward’s cumulative equity raised since its 2024 founding to approximately $590 million (following a $200 million Series A in January 2025 and a $165 million Series B in May 2026).

Across its two licensing pacts, Windward committed $70 million in combined upfront cash and equity plus roughly $1.6 billion in potential milestones:

| Asset (China Code)                           | Chinese Originator(s)                                             | Deal Terms & Equity Structure                                                                                                                                                     | Clinical Status & Benchmark                                                                                                                            |
| -------------------------------------------- | ----------------------------------------------------------------- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------ |
| **WIN378** (HBM9378 / SKB378, anti-TSLP mAb) | Harbour BioMed (02142.HK) & Kelun-Biotech (06990.HK, 50/50 split) | Up to **$970 million** upfront + milestones (incl. **$45 million** cash/equity upfront & near-term fees) + tiered royalties; licensors keep Greater China & parts of SE/West Asia | Seamless Phase II/III POLARIS-1 (NCT07120503, n=147 in Ph2) chose **twice-yearly** dosing for Ph3 severe asthma; Ph2 COPD SIRIUS (NCT07646587) ongoing |
| **WIN027** (QX027N, TSLP x IL-13 bispecific) | Qyuns Therapeutics (02509.HK)                                     | Up to **$700 million** total (undisclosed cash upfront + Windward equity + milestones) + tiered royalties; Qyuns keeps Greater China (QX027N)                                     | Global Phase I showed 62-day half-life; global Ph2b COPD & Ph2 AD start H1 2027; Qyuns started China Ph2 AD & CRSwNP in Sep 2026                       |

For the Chinese originators, equity-linked licensing has already reshaped near-term income statements without resolving long-term valuation capture. In its H1 2026 interim filing, Qyuns reported RMB 424.1 million (approx. $58.9 million) in revenue—up 105.4% year-on-year—and swung to a RMB 203 million (approx. $28.2 million) interim profit, driven primarily by RMB 378.6 million in licensing revenue that included upfront cash and non-cash Windward equity for `QX027N` (alongside Roche and Joincare deals). Harbour and Kelun-Biotech likewise hold equity stakes in Windward’s parent plus change-of-control and sublicense participation clauses, though Windward controls ex-China clinical execution and capital allocation.

## Twice-yearly TSLP into a crowded respiratory arena

Clinically, Windward’s pitch rests on dosing convenience against Amgen and AstraZeneca’s approved anti-TSLP blockbuster `Tezspire` (`tezepelumab`, FDA `BLA761224`), which is dosed every four weeks and generated roughly $2 billion in annual sales. At the [September 2026 interim readout](https://www.harbourbiomed.com/news/1482.html?ref=chinapharmadesk.com) from the 147-patient Phase II dose-finding portion of `POLARIS-1` (n=98 analyzed), `WIN378` improved lung function and airway inflammation biomarkers enough to advance two twice-yearly regimens into the Phase III asthma portion, with a second Phase III study (`POLARIS-2`) slated for H1 2027.

Yet the long-acting TSLP niche already carries an expensive Chinese precedent: in 2024, GSK paid $1 billion upfront to acquire Aiolos Bio, whose long-acting anti-TSLP candidate `AIO-001` (`SHR-1905`) originated at Jiangsu Hengrui Pharmaceuticals (SSE: 600276; HKEX: 01276). Meanwhile, Qyuns itself runs a parallel domestic TSLP program, `QX008N` (`JKN2401`), licensed to Joincare in China and in a Phase III COPD study since March 2026.

## Next evidence triggers

1. **Closing and initial public float performance** of Windward’s $225 million offering on **November 16, 2026**, plus any 30-day greenshoe exercise and disclosures on Harbour, Kelun-Biotech, and Qyuns post-IPO equity stakes in subsequent HKEX filings.
2. **First half of 2027 clinical catalysts**: `POLARIS-2` Phase III asthma initiation and full Phase II `POLARIS-1` presentation for `WIN378`, plus full Phase I PK/immunogenicity data and global Phase IIb COPD / Phase II AD enrollment starts for `WIN027` (`QX027N`).
3. **December 2027 primary completion** of `SIRIUS` (`NCT07646587`) in COPD and **October 2028 primary completion** of `POLARIS-1` (`NCT07120503`), which will test whether six-month dosing matches monthly TSLP efficacy on exacerbations.